Payment overview · 2025
General Payments
$318.56
14 reported records · 9 companies
Healthcare provider profile · identity verified
Ram K Kamath, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · APPLE VALLEY, CA · NPI 1386649556
Verified facts
What the public records show
CMS Open Payments records show Ram K Kamath, M.D. received $318.56 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.96 | 25.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.69 | 19.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.06 | 17.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.50 | 8.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.55 | 8.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.28 | 6.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.95 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.37 | 4.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.20 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.56 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $79.96 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.69 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.06 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Respiratory Normalized: respiratory |
Device | Philips North America LLC | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 104 |
| Lisinopril | Lisinopril | 313 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 67 |
| Metformin Hcl | Metformin Hcl | 234 | 68 |
| Omeprazole | Omeprazole | 208 | 45 |
| Gabapentin | Gabapentin | 179 | 54 |
| Simvastatin | Simvastatin | 174 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 44 |
| Alendronate Sodium | Alendronate Sodium | 156 | 44 |
| Losartan Potassium | Losartan Potassium | 153 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 39 |
| Furosemide | Furosemide | 119 | 40 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 111 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 32 |
| Tramadol Hcl | Tramadol Hcl | 87 | 43 |
| Levetiracetam | Levetiracetam | 85 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 14 |
| Donepezil Hcl | Donepezil Hcl | 82 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 27 |
| Sertraline Hcl | Sertraline Hcl | 82 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 23 |
| Trazodone Hcl | Trazodone Hcl | 77 | 21 |
| Naproxen | Naproxen | 75 | 26 |
| Glipizide | Glipizide | 73 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 70 | 26 |
| Famotidine | Famotidine | 69 | 22 |
| Alprazolam | Alprazolam | 68 | 19 |
| Ibuprofen | Ibuprofen | 68 | 34 |
| Montelukast Sodium | Montelukast Sodium | 65 | 12 |
| Finasteride | Finasteride | 61 | 16 |
| Atenolol | Atenolol | 60 | suppressed |
| Olanzapine | Olanzapine | 60 | suppressed |
| Potassium Chloride | Potassium Chloride | 60 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | suppressed |
| Allopurinol | Allopurinol | 56 | 15 |
| Buspirone Hcl | Buspirone Hcl | 56 | 14 |
| Baclofen | Baclofen | 55 | suppressed |
| Carvedilol | Carvedilol | 54 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 13 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 19 |
| Risperidone | Risperidone | 46 | 11 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Lorazepam | Lorazepam | 44 | 16 |
| Cephalexin | Cephalexin | 42 | 30 |
| Jardiance | Empagliflozin | 42 | 12 |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 34 |
| Nystatin | Nystatin | 38 | 13 |
| Hydrocortisone | Hydrocortisone | 37 | 20 |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Lactulose | Lactulose | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 18 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Ozempic | Semaglutide | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Prednisone | Prednisone | 19 | 11 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.56 · 14 records | Amgen Inc. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, GVOKE HYPOPEN, KRYSTEXXA, Kerendia, MOUNJARO, PREVNAR 20, REXULTI, Respiratory | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error